Digital follow-up for safer cancer treatment
Monitoring of Adverse Events Caused by Systemic Cancer Treatment. Identifying Adverse Events Related to Immunotherapy Treatment Before and After Implementation of Personalized Digital Patient Reported Outcomes
This study tests if a personalized digital follow-up program can help cancer patients on immunotherapy feel safer and healthier compared to regular check-ups.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 900 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nordlandssykehuset HF Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Bodø, Nordland) |
| Trial ID | NCT06476158 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the impact of a personalized digital follow-up program on cancer patients receiving immunotherapy. Participants will report their symptoms directly to healthcare personnel through a digital platform, allowing for real-time monitoring of adverse events and overall health. The study compares outcomes between patients using this digital system and those receiving standard follow-up care. The goal is to enhance patient safety, quality of life, and survival rates by improving the detection of treatment-related harm.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with a cancer diagnosis who are receiving immunotherapy as part of their treatment.
Not a fit: Patients with hematological or gynecological cancers may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to safer cancer treatments and improved quality of life for patients undergoing immunotherapy.
How similar studies have performed: Other studies have shown promise in using digital tools for patient monitoring, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Above 18 years of age * Cancer diagnosis as primary or secondary diagnosis according to the ICD-10 classification * Receiving immunotherapy as systemic anticancer treatment reported with ATC codes for medications. Exclusion Criteria: * Hematological cancer * Gynecological cancer
Where this trial is running
Bodø, Nordland
- Nordlandssykehuset HF — Bodø, Nordland, Norway (Recruiting)
Study contacts
- Study coordinator: Ellinor C Haukland, MD, Phd
- Email: ellinor.haukland@nlsh.no
- Phone: +4792267328
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.